The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta‐analysis of randomized controlled trials
- 25 August 2023
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (1) , 52-61
Abstract
Janus kinase (JAK) inhibitors have been recently approved by the FDA and are widely used in the treatment of patients with atopic dermatitis. However, a comprehensive safety profile of JAK inhibitors in patients with atopic dermatitis has not been analysed. This study aimed to establish clinical evidence for the safety of systemic JAK inhibitors in patients with atopic dermatitis. Medline, Embase, Clinicaltrials.gov, Cochrane Central Register of Controlled Trials (CENTRAL) and International Clinical Trials Registry Platform (ICTRP) were considered for search databases. Randomized controlled trials reporting the adverse events of systemic therapy in patients with atopic dermatitis were included. The risk of 11 adverse events was compared between the JAK inhibitors and placebo groups. Fourteen randomized controlled trials were analysed published between 2019 and 2022. The JAK inhibitors included in the analysis were abrocitinib (10, 30, 100 and 200 mg), baricitinib (1, 2 and 4 mg) and upadacitinib (7.5, 15 and 30 mg). The risk of herpes zoster, headache, acne, elevated blood creatinine phosphokinase and nausea was significantly increased, but the risk of serious infection, non‐melanoma skin cancer (NMSC), malignancies other than NMSC, major adverse cardiovascular event, venous thromboembolism and nasopharyngitis was not increased. This study provides comprehensive clinical evidence on the risk of various adverse events in patients with atopic dermatitis. However, since the follow‐up periods of the studies analysed in this review were mostly limited to 16 weeks or less, it is recommended that comprehensive long‐term observational studies be conducted to determine any potential adverse events associated with major cardiovascular events or malignancies, which typically have prolonged courses.Keywords
Funding Information
- National Research Foundation of Korea (NRF‐2018R1A5A2023879, NRF‐2021R1I1A3044245, NRF‐2022R1C1C1007391, RS‐2023‐00207946)
- Korea Research Environment Open Network
This publication has 48 references indexed in Scilit:
- Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-AnalysisOpen Forum Infectious Diseases, 2016
- Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseasesNature Reviews Rheumatology, 2015
- Grading the strength of a body of evidence when assessing health care interventions: an EPC updateJournal of Clinical Epidemiology, 2015
- Statistical methods for dealing with publication bias in meta‐analysisStatistics in Medicine, 2014
- Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatmentRheumatology, 2014
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Measuring inconsistency in meta-analysesBMJ, 2003
- Rheumatoid arthritis and cancer riskEuropean Journal of Cancer, 1996
- STAT Activation by Epidermal Growth Factor (EGF) and AmphiregulinJournal of Biological Chemistry, 1996
- Estimation of a Common Effect Parameter from Sparse Follow-Up Data1985